peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

peptide-drug conjugate

Melflufen

Published evidence · coverage incomplete

Anatomy in the research

Anatomy evidence is still being assembled.

These are anatomical mentions in cited research—not established treatment targets or proof of benefit in people.

This publication has no anatomy passages that meet our source-linking checks yet. Read the available findings ↓

General anatomy view only. No peptide-specific structures are highlighted.

At a glance

What is it—and why does it matter?

Melflufen is described as a peptide–drug conjugate prodrug designed to deliver the alkylating agent melphalan. With a median follow-up duration of 5.75 months, the overall survival curve had not reached the median in this melflufen–dexamethasone cohort.

Sources for this introduction: [1] [2]

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

Identity

Melflufen is described as a peptide–drug conjugate prodrug designed to deliver the alkylating agent melphalan.

Sources[3]pubmedEfficacy of melflufen in multiple myeloma with mutated or deleted TP53.melflufen (melphalan flufenamide)[2]pubmedOptimizing the use of melflufen (melphalan flufenamide) in relapsed or refractory multiple myeloma: recommendations for clinical practice.Melflufen, a first-in-class peptide-drug conjugate[2]pubmedOptimizing the use of melflufen (melphalan flufenamide) in relapsed or refractory multiple myeloma: recommendations for clinical practice.melflufen (melphalan flufenamide)[1]pubmedExceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?melflufen (a peptide-drug conjugate pro-drug of melphalan)[4]pubmedPositioning of Melflufen in Heavily Pretreated RRMM Patients: Real-World Evidence in a Rapidly Evolving Therapeutic Landscape.Melflufen (melphalan-flufenamide) plus dexamethasone[5]pubmedMelflufen in Multiple Myeloma: Clinical Limitations, Biological Rationale, and Future Perspectives.Melflufen (melphalan flufenamide)
Source records
6
Independent studies
5

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “melflufen (melphalan flufenamide)”

    Efficacy of melflufen in multiple myeloma with mutated or deleted TP53. · Abstract

    pubmed:41437395:1a8db8601b79:1a8db8601b79
  2. supports · Source-backed record
    “Melflufen, a first-in-class peptide-drug conjugate”

    Optimizing the use of melflufen (melphalan flufenamide) in relapsed or refractory multiple myeloma: recommendations for clinical practice. · Abstract

    pubmed:41207923:bdd9cc437c00:bdd9cc437c00
  3. supports · Source-backed record
    “melflufen (melphalan flufenamide)”

    Optimizing the use of melflufen (melphalan flufenamide) in relapsed or refractory multiple myeloma: recommendations for clinical practice. · Abstract

    pubmed:41207923:bdd9cc437c00:bdd9cc437c00
  4. supports · Source-backed record
    “melflufen (a peptide-drug conjugate pro-drug of melphalan)”

    Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies? · Abstract

    pubmed:41065854:0ad5255cf0e7:0ad5255cf0e7
  5. supports · Source-backed record
    “Melflufen (melphalan-flufenamide) plus dexamethasone”

    Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real-World Evidence in a Rapidly Evolving Therapeutic Landscape. · Abstract

    pubmed:41813608:eed0813f961b:eed0813f961b
  6. supports · Source-backed record
    “Melflufen (melphalan flufenamide)”

    Melflufen in Multiple Myeloma: Clinical Limitations, Biological Rationale, and Future Perspectives. · Abstract

    pubmed:42192911:29849c8a34c3:29849c8a34c3

How does it work?

Target, response, and disposition.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

What has been studied?

What the evidence says.

Study findings

With a median follow-up duration of 5.75 months, the overall survival curve had not reached the median in this melflufen–dexamethasone cohort.

Sources[6]pubmedReal-World Outcomes of Melflufen Plus Dexamethasone in Heavily Pretreated Relapsed/Refractory Multiple Myeloma After Exposure to Immunotherapies.At a median follow-up of 5.75 months, median overall survival was not reached.
Reported result
median overall survival was not reached
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “At a median follow-up of 5.75 months, median overall survival was not reached.”

    Real-World Outcomes of Melflufen Plus Dexamethasone in Heavily Pretreated Relapsed/Refractory Multiple Myeloma After Exposure to Immunotherapies. · RESULTS

    pubmed:42270486:2c8dd0b57466:2c8dd0b57466

Study findings

Time-to-event outcome for melflufen–dexamethasone showed a median progression-free survival of 4.8 months, with a 95% confidence interval from 2.5 months to not reached.

Sources[6]pubmedReal-World Outcomes of Melflufen Plus Dexamethasone in Heavily Pretreated Relapsed/Refractory Multiple Myeloma After Exposure to Immunotherapies.Median progression-free survival was 4.8 months (95% CI: 2.5-not reached).
Reported result
4.8 months (95% CI: 2.5-not reached)
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Median progression-free survival was 4.8 months (95% CI: 2.5-not reached).”

    Real-World Outcomes of Melflufen Plus Dexamethasone in Heavily Pretreated Relapsed/Refractory Multiple Myeloma After Exposure to Immunotherapies. · RESULTS

    pubmed:42270486:2c8dd0b57466:2c8dd0b57466

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, interaction, mechanism, regulatory, safety
  • 62 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (25), assurance_score_below_0.72 (28), current_regulatory_source_required (12), extraction_ambiguity (54), high_risk_requires_regulatory_or_two_independent_sources (37), no_direct_support (53)

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies? ↗

    pubmed · published 2025-10-09 · retrieved 2026-08-28T12:35:21Z

  2. Optimizing the use of melflufen (melphalan flufenamide) in relapsed or refractory multiple myeloma: recommendations for clinical practice. ↗

    pubmed · published 2025-11-01 · retrieved 2026-08-28T12:35:21Z

  3. Efficacy of melflufen in multiple myeloma with mutated or deleted TP53. ↗

    pubmed · published 2025-12-23 · retrieved 2026-08-28T12:35:21Z

  4. Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real-World Evidence in a Rapidly Evolving Therapeutic Landscape. ↗

    pubmed · published 2026-06-01 · retrieved 2026-08-28T12:35:21Z

  5. Melflufen in Multiple Myeloma: Clinical Limitations, Biological Rationale, and Future Perspectives. ↗

    pubmed · published 2026-05-11 · retrieved 2026-08-28T12:35:21Z

  6. Real-World Outcomes of Melflufen Plus Dexamethasone in Heavily Pretreated Relapsed/Refractory Multiple Myeloma After Exposure to Immunotherapies. ↗

    pubmed · published 2026-08-01 · retrieved 2026-08-28T12:35:21Z

Publication history and provenance

Version 2 · Automated assessment · 2026-08-28T12:35:21Z

d4d11c01ea759772901950440ca6f6bb89d126281eac09ce2711e958d7cb9820